Trevenans

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

This research aims to evaluate a newly developed tool designed to assess the condition of the oral cavity in adult patients who are orally intubated in intensive care units. Oro-tracheal intubation often causes lesions in the mouth and throat, which can affect the patients hospital stay and quality of life. Currently, no assessment tools are specifically adapted for these intubated patients, highlighting the need for a specialized evaluation method. The study involves using the new Mouth Assessment Tool MAT by nurses to evaluate the oral condition of adults undergoing oro-tracheal intubation in intensive care. This tool has been created with input from experts in intensive care, oral health, hygiene, wound healing, and patient partners to ensure relevance and usability in daily nursing practice. The study will assess the tools metrological performance, content validity, construct validity, and reliability at the time of patient inclusion. Participants will be adults in intensive care who are orally intubated. Nurses will use the MAT to assess oral health at inclusion Day 0. Researchers will monitor how well the tool measures oral condition, its validity, and consistency. The study will evaluate the tools ability to support better mouth care protocols and improve patient outcomes by providing accurate assessments. The trial is observational and will continue until October 2028.

Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to standard care in hospitalized adults with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, double-blind study aims to compare trimodulin plus standard care against placebo plus standard care. The study also investigates detailed pharmacokinetic and pharmacodynamic properties of trimodulin. Participants will be randomly assigned to receive either trimodulin a human immunoglobulin solution containing IgM, IgA, and IgG or a placebo human albumin 1% via intravenous infusion once daily for five consecutive days alongside standard care. After treatment, participants will enter a follow-up phase lasting up to 23 days, including an end-of-follow-up visit or phone call on day 29. If still hospitalized after day 29, extended follow-up continues until discharge or day 90, followed by a closing visit or call around day 91. During the study, participants undergo various assessments including monitoring of mortality rates up to 28 and 90 days, changes in organ failure scores, clinical cure of pneumonia, ventilator and oxygen use, ICU and hospital stay durations, readmission rates, adverse events, lab tests, electrocardiograms, and vital signs. Safety evaluations and outcome measurements occur throughout treatment and follow-up, with total participation lasting up to approximately 90 days.

Researchers are studying the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis both radiographic and non-radiographic or psoriatic arthritis. This study aims to better understand how salt consumption may influence these conditions and the response to certain therapies targeting inflammation, specifically anti IL-17A agents. The study is sponsored by the Centre Hospitalier Universitaire de Besancon and includes adults aged 18 to 80 with these arthritis conditions. Participants will be patients with radiographic or non-radiographic axial spondylitis or psoriatic arthritis who are managed in rheumatology departments at study centers. The study involves measuring the participants salt intake during the day of inclusion and the following Monday and Tuesday. There is no intervention to change sodium intake instead, the study focuses on assessing and analyzing salt consumption and its possible effects on disease activity. During the study, participants will have their dietary sodium intake monitored and recorded. Researchers will evaluate the sodium intake data collected over three days to see how it relates to disease activity and therapeutic response. The study includes follow-up assessments during these days but does not involve any medication or treatment changes. Participation will last for the short period needed to measure sodium intake, with safety monitoring as needed according to the patients usual care.

Researchers are evaluating the safety of using trifluridinetipiracil as a replacement for fluoropyrimidine-based chemotherapy in patients with dihydropyrimidine dehydrogenase DPD deficiency who have metastatic colorectal or gastroesophageal cancer. This phase II trial aims to determine if this alternative chemotherapy is safer and whether combining it with other treatments improves progression-free survival, overall survival, response rates, disease control, and quality of life. Participants will receive trifluridinetipiracil orally along with oxaliplatin intravenously every 14 days. Depending on tumor type, they may also receive panitumumab or bevacizumab for colorectal cancer, or nivolumab or trastuzumab for gastroesophageal cancer. Treatments are given in cycles every two weeks, and the trial includes different combinations based on cancer biomarkers. During the study, participants will have CT scans every two months to monitor disease progression. They will complete quality of life questionnaires at baseline and every two months for up to six months. Optional blood samples will be collected for genetic and pharmacokinetic research. The primary outcome is treatment-specific safety measured within one month, with secondary outcomes including overall safety, treatment compliance, survival rates, tumor response, and quality of life assessments over up to two years.